USE OF EXENDINS AND EXENDIN AGONISTS AND GLP-1 RECEPTOR AGONISTS FOR ALTERING LIPOPROTEIN PARTICLE SIZE AND SUBCLASS COMPOSITION
The present invention relates to altering the concentration of various lipid molecules, specifically for example by shifting from small LDL particles to large LDL and HDL particles. The present invention also relates to methods for increasing average lipid particle size and methods for improving the cardiovascular risk profile of a subject by altering lipid particle sizes or concentrations or both.